Registre Français de la maladie de Pompe. Caractérisation d’une cohorte de 126 patients adultes
P. Laforêt, K. Laloui, B. Granger, D. Hamroun, N. Taouagh, JY. Hogrel, D. Orlikowski, F. Bouhour, A. Lacour, E. Salort-Campana, I. Penisson-Besnier, S. Sacconi, F. Zagnoli, F. Chapon, B. Eymard, C. Desnuelle, J. Pouget et le French Pompe Registry Study Group
Revue neurologique. 2013. 169:595-602.
The French Pompe registry was created in 2004 with the initial aim of studying the natural history of French patients with adult Pompe disease. Since the marketing in 2006 of enzyme replacement therapy (alglucosidase alfa, Myozyme1), the French Pompe registry has also been used to prospectively gather the biological and clinical follow-up data of all adult patients currently treated in France.
This report describes the main clinical and molecular features, at the time of inclusion in the French registry, of 126 patients followed up in 21 hospital-based neuromuscular or metabolic centers. The MFM, which has been used to evaluate the level of impairment of muscle function, appears to be a useful tool, particularly with regard to the D1 domain. Good correlations between MFM scores and 6MWT confirmed the importance of the MFM measurement in the follow-up of patients with Pompe disease.
Keywords: Pompe disease, Pompe registry, Acid alpha-glucosidase deficiency
Articles in scientific journals
Muscular involvement assessed by MRI correlates to motor function measurement values in oculopharyngeal muscular dystrophy
Fischmann A, Gloor M, Fasler S, Haas T, Rodoni Wetzel R, Bieri O, Wetzel S, Heinimann K, Scheffler K, Fischer D. J Neurol 2011. 258: 1333–1340. Oculopharyngeal muscular dystrophy (OPMD) is a progressive skeletal muscle dystrophy characterized by ptosis, dysphagia, and...
Impaired Mandibular Function in Spinal Muscular Atrophy Type II: Need for Early Recognition
van Bruggen HW, van den Engel-Hoek L, van der Pol WL, de Wijer A, de Groot IJ, Steenks MH. J Child Neurol. Nov 2011. 26: 1392 - 1396. The aim of the study is to assess mandibular function in young patients with spinal muscular atrophy type II. The mandibular function...
Idebenone for the treatment of Duchenne muscular dystrophy (Protocol)
Geng J, Dong J, Jiang K, Shen L, Wu T, Ni H, Shi LL, Wang G, Wu H. The Cochrane Library 2011. Description of a protocol aiming at assessing efficacy of ibedenone on muscle strength, muscle function, lung function, cardiac function and quality of life for patients with...
High-frequency, low-intensity vibrations increase bone mass and muscle strength in upper limbs, improving autonomy in disabled children
Reyes ML, Hernandez M, Holmgren LJ, Sanhueza E, Escobar RG. J Bone Miner Res, 2011. 26(8): 1759-66. The main objective of this study was to evaluate the efficacy and safety of high-frequency, low-magnitude vibration, in patients with disabilities. 55 children were a...
Motor Function Measure Scale (MFM): New Instrument for Follow-Up Brazilian Patients with Neuromuscular Disease
Iwabe C, Nucci A, Pfeilsticker BHM, Magna LA. Muscular Dystrophy ed.Croacia : Intech. 2012. 303-320. Book chapter presenting the validation and applicability of the MFM Portuguese version.Link Articles dans les revues scientifiques
Recombinant human acid alpha-glucosidase (rhGAA) in adult patients with severe respiratory failure due to Pompe disease
Orlikowski D, Pellegrini N, Prigent H, Laforêt P, Carlier R, Carlier P, Eymard B, Lofaso F, Annane D. Neuromuscul Disord. 2011. 21(7):477-82. This open-label prospective exploratory study investigated the effect of 12 months of recombinant enzyme replacement therapy...